Do analysts rate VVOS or DYNT?

Vivos Therapeutics presently has a consensus target price of $2.80, suggesting a potential upside of 1,615.69%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than Dynatronics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, VRAX or DYNT?

Dynatronics has higher revenue and earnings than Virax Biolabs Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 203.20 -$5.02M N/A N/A Dynatronics $33.60M 0.00 -$2.70M -$1.35 N/A

Is BTCY or DYNT more profitable?

Dynatronics has a net margin of -8.35% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat Dynatronics' return on equity. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% Dynatronics -8.35% -41.81% -9.56%

Do analysts recommend GCTK or DYNT?

Given Dynatronics' higher possible upside, analysts clearly believe Dynatronics is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GCTK or DYNT more profitable?

GlucoTrack has a net margin of 0.00% compared to Dynatronics' net margin of -8.35%. Dynatronics' return on equity of -41.81% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -2,135.52% -290.22% Dynatronics -8.35% -41.81% -9.56%

Does the media favor GCTK or DYNT?

In the previous week, GlucoTrack had 1 more articles in the media than Dynatronics. MarketBeat recorded 2 mentions for GlucoTrack and 1 mentions for Dynatronics. GlucoTrack's average media sentiment score of 0.66 beat Dynatronics' score of 0.00 indicating that GlucoTrack is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dynatronics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend DYNT or BBLG?

Given Dynatronics' higher possible upside, equities analysts plainly believe Dynatronics is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Dynatronics (DYNT) Competitors

Compare

DYNT vs. VVOS, VRAX, BTCY, GCTK, and BBLG

Should you buy Dynatronics stock or one of its competitors? Dynatronics's main competitors and comparable companies include Vivos Therapeutics (VVOS), Virax Biolabs Group (VRAX), Biotricity (BTCY), GlucoTrack (GCTK), and Bone Biologics (BBLG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Dynatronics compare to Vivos Therapeutics?

Vivos Therapeutics (NASDAQ:VVOS) and Dynatronics (NASDAQ:DYNT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Vivos Therapeutics presently has a consensus target price of $2.80, suggesting a potential upside of 1,615.69%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than Dynatronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Dynatronics shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by insiders. Comparatively, 2.9% of Dynatronics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vivos Therapeutics has a beta of 6.04, suggesting that its stock price is 504% more volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

In the previous week, Dynatronics had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 1 mentions for Dynatronics and 0 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score.

Company	Overall Sentiment
Vivos Therapeutics	Neutral
Dynatronics	Neutral

Dynatronics has a net margin of -8.35% compared to Vivos Therapeutics' net margin of -122.00%. Dynatronics' return on equity of -41.81% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
Dynatronics	-8.35%	-41.81%	-9.56%

Dynatronics has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.13	-$21.17M	-$1.90	N/A
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A

Summary

Dynatronics beats Vivos Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Dynatronics compare to Virax Biolabs Group?

Virax Biolabs Group (NASDAQ:VRAX) and Dynatronics (NASDAQ:DYNT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 4.2% of Dynatronics shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 2.9% of Dynatronics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Virax Biolabs Group has a net margin of 0.00% compared to Dynatronics' net margin of -8.35%. Virax Biolabs Group's return on equity of 0.00% beat Dynatronics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Dynatronics	-8.35%	-41.81%	-9.56%

Dynatronics has higher revenue and earnings than Virax Biolabs Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	203.20	-$5.02M	N/A	N/A
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A

In the previous week, Dynatronics had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 1 mentions for Dynatronics and 0 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Dynatronics	Neutral

Virax Biolabs Group presently has a consensus price target of $25.00, indicating a potential upside of 884.25%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Virax Biolabs Group is more favorable than Dynatronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virax Biolabs Group has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Summary

Virax Biolabs Group beats Dynatronics on 9 of the 12 factors compared between the two stocks.

How does Dynatronics compare to Biotricity?

Biotricity (NASDAQ:BTCY) and Dynatronics (NASDAQ:DYNT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

3.9% of Biotricity shares are held by institutional investors. Comparatively, 4.2% of Dynatronics shares are held by institutional investors. 1.6% of Biotricity shares are held by company insiders. Comparatively, 2.9% of Dynatronics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biotricity has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

In the previous week, Dynatronics had 1 more articles in the media than Biotricity. MarketBeat recorded 1 mentions for Dynatronics and 0 mentions for Biotricity. Biotricity's average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score.

Company	Overall Sentiment
Biotricity	Neutral
Dynatronics	Neutral

Dynatronics has higher revenue and earnings than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.14	-$14.09M	-$0.14	N/A
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A

Dynatronics has a net margin of -8.35% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat Dynatronics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
Dynatronics	-8.35%	-41.81%	-9.56%

Summary

Dynatronics beats Biotricity on 8 of the 11 factors compared between the two stocks.

How does Dynatronics compare to GlucoTrack?

GlucoTrack (NASDAQ:GCTK) and Dynatronics (NASDAQ:DYNT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Given Dynatronics' higher possible upside, analysts clearly believe Dynatronics is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dynatronics has higher revenue and earnings than GlucoTrack. GlucoTrack is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A

GlucoTrack has a net margin of 0.00% compared to Dynatronics' net margin of -8.35%. Dynatronics' return on equity of -41.81% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-2,135.52%	-290.22%
Dynatronics	-8.35%	-41.81%	-9.56%

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 4.2% of Dynatronics shares are owned by institutional investors. 5.9% of GlucoTrack shares are owned by insiders. Comparatively, 2.9% of Dynatronics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, GlucoTrack had 1 more articles in the media than Dynatronics. MarketBeat recorded 2 mentions for GlucoTrack and 1 mentions for Dynatronics. GlucoTrack's average media sentiment score of 0.66 beat Dynatronics' score of 0.00 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GlucoTrack	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dynatronics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GlucoTrack has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Summary

GlucoTrack and Dynatronics tied by winning 7 of the 14 factors compared between the two stocks.

How does Dynatronics compare to Bone Biologics?

Dynatronics (NASDAQ:DYNT) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Dynatronics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Dynatronics has higher revenue and earnings than Bone Biologics. Bone Biologics is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A

4.2% of Dynatronics shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 2.9% of Dynatronics shares are owned by insiders. Comparatively, 5.0% of Bone Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bone Biologics has a net margin of 0.00% compared to Dynatronics' net margin of -8.35%. Dynatronics' return on equity of -41.81% beat Bone Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dynatronics	-8.35%	-41.81%	-9.56%
Bone Biologics	N/A	-57.87%	-53.65%

In the previous week, Dynatronics had 1 more articles in the media than Bone Biologics. MarketBeat recorded 1 mentions for Dynatronics and 0 mentions for Bone Biologics. Dynatronics' average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
Dynatronics	Neutral
Bone Biologics	Neutral

Given Dynatronics' higher possible upside, equities analysts plainly believe Dynatronics is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Dynatronics beats Bone Biologics on 8 of the 13 factors compared between the two stocks.

Get Dynatronics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYNT vs. The Competition

Export

Metric	Dynatronics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$653K	$5.57B	$7.24B	$13.21B
Dividend Yield	N/A	1.80%	2.57%	12.80%
P/E Ratio	-0.01	25.34	275.49	25.40
Price / Sales	N/A	43.73	639.63	86.88
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	N/A	5.69	10.46	6.33
Net Income	-$2.70M	$151.55M	$3.49B	$358.33M

Dynatronics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYNT Dynatronics	N/A	N/A	N/A	N/A	$653K	$33.60M	N/A	200	News Coverage
VVOS Vivos Therapeutics	1.6883 of 5 stars	$0.16 +0.2%	$2.80 +1,607.3%	-95.3%	$2.25M	$17.44M	N/A	160
VRAX Virax Biolabs Group	2.7237 of 5 stars	$2.55 -1.7%	$25.00 +882.3%	-83.8%	$2.04M	$10K	N/A	5	Positive News
BTCY Biotricity	N/A	$0.10 +0.8%	N/A	-86.6%	$1.93M	$12.06M	N/A	40	Gap Up
GCTK GlucoTrack	0.9675 of 5 stars	$2.25 -0.9%	N/A	-97.5%	$1.60M	N/A	N/A	5	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYNT) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dynatronics (DYNT) Competitors

DYNT vs. VVOS, VRAX, BTCY, GCTK, and BBLG

How does Dynatronics compare to Vivos Therapeutics?

Summary

How does Dynatronics compare to Virax Biolabs Group?

Summary

How does Dynatronics compare to Biotricity?

Summary

How does Dynatronics compare to GlucoTrack?

Summary

How does Dynatronics compare to Bone Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYNT vs. The Competition

Dynatronics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dynatronics (DYNT) Competitors

DYNT vs. VVOS, VRAX, BTCY, GCTK, and BBLG

How does Dynatronics compare to Vivos Therapeutics?

Do analysts rate VVOS or DYNT?

Do insiders and institutionals hold more shares of VVOS or DYNT?

Which has more risk & volatility, VVOS or DYNT?

Does the media prefer VVOS or DYNT?

Is VVOS or DYNT more profitable?

Which has stronger valuation and earnings, VVOS or DYNT?

Summary

How does Dynatronics compare to Virax Biolabs Group?

Do insiders & institutionals believe in VRAX or DYNT?

Is VRAX or DYNT more profitable?

Which has better earnings and valuation, VRAX or DYNT?

Does the media refer more to VRAX or DYNT?

Do analysts recommend VRAX or DYNT?

Which has more risk & volatility, VRAX or DYNT?

Summary

How does Dynatronics compare to Biotricity?

Do insiders and institutionals have more ownership in BTCY or DYNT?

Which has more risk & volatility, BTCY or DYNT?

Does the media refer more to BTCY or DYNT?

Which has stronger valuation and earnings, BTCY or DYNT?

Is BTCY or DYNT more profitable?

Summary

How does Dynatronics compare to GlucoTrack?

Do analysts recommend GCTK or DYNT?

Which has higher valuation and earnings, GCTK or DYNT?

Is GCTK or DYNT more profitable?

Do institutionals & insiders hold more shares of GCTK or DYNT?

Does the media favor GCTK or DYNT?

Which has more risk & volatility, GCTK or DYNT?

Summary

How does Dynatronics compare to Bone Biologics?

Which has more volatility and risk, DYNT or BBLG?

Which has preferable valuation and earnings, DYNT or BBLG?

Do institutionals and insiders hold more shares of DYNT or BBLG?

Is DYNT or BBLG more profitable?

Does the media refer more to DYNT or BBLG?

Do analysts recommend DYNT or BBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYNT vs. The Competition

Dynatronics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools